Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAIN SCIENTIFIC INC.BRSF · Entity 124256 | Director | August 19, 2022 | August 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAIN SCIENTIFIC INC.
Report date August 19, 2022 · Filed August 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2027-08-19 | Direct | 304,608 |
Reported balance
After 2022-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-19 · Grant · Acquired 304,608 · Balance 304,608 F1: 304,608 stock options (the "Options") were granted to Mr. Kukekov on August 19, 2022 (the "Date of Grant"), pursuant to the Brain Scientific 2022 Stock Incentive Plan. The Options shall vest and become exercisable on the following schedule: (i) 61,552 Options shall vest immediately, (ii) 69,444 Options shall vest on August 30, 2022, (iii) 69,444 Options shall vest on September 30, 2022, (iv) 69,444 Options shall vest on October 30, 2022, and (v) 34,724 Options shall vest on November 15, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 304,608 stock options (the "Options") were granted to Mr. Kukekov on August 19, 2022 (the "Date of Grant"), pursuant to the Brain Scientific 2022 Stock Incentive Plan. The Options shall vest and become exercisable on the following schedule: (i) 61,552 Options shall vest immediately, (ii) 69,444 Options shall vest on August 30, 2022, (iii) 69,444 Options shall vest on September 30, 2022, (iv) 69,444 Options shall vest on October 30, 2022, and (v) 34,724 Options shall vest on November 15, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BioRestorative Therapies, Inc.
Report date February 14, 2025 · Filed February 19, 2025
Section 16 reporting ended · disclosed 2024-02-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 52,632 |
Reported balance
After 2025-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-14 · Grant · Acquired 52,632 · Balance 52,632 F2: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing each month thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 25,236 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 25,236 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 32,028 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 32,028 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 79,646 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 79,646 F1: The option is currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing each month thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 19, 2025 21:29 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 52,632 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001021771-25-000042 · form4.xml · derivative · entry 4 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,632 Underlying: Common Stock · 52,632 shares Expires 2035-02-14 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing each month thereafter until fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 79,646 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001021771-24-000052 · form4.xml · derivative · entry 3 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,646 Underlying: Common Stock · 79,646 shares Expires 2033-02-13 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve nearly equal monthly installments of 6,637 shares beginning on March 13, 2024 and continuing each month thereafter until fully vested. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 22:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 32,028 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001567619-23-003330 · doc1.xml · derivative · entry 2 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,028 Underlying: Common Stock · 32,028 shares Expires 2033-02-17 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve monthly installments of 2,669 shares beginning on March 17, 2023 and continuing each month thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:22 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 25,236 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019193 · doc1.xml · derivative · entry 2 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,236 Underlying: Common Stock · 25,236 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 12,618 shares on November 4, 2021 with the remaining 12,618 shares vesting quarterly in eight nearly equal installments beginning November 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:22 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 25,236 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019193 · doc1.xml · derivative · entry 1 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,236 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 12,618 shares on November 4, 2021 with the remaining 12,618 shares vesting quarterly in eight nearly equal installments beginning November 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| August 19, 2022 Filed Aug 24, 2022 17:17 UTC | BRAIN SCIENTIFIC INC. BRSF · Entity 124256 | GrantOptions to purchase Common Stock · Derivative | 304,608 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001213900-22-050836 · ownership.xml · derivative · entry 1 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,608 Underlying: Common Stock · 304,608 shares Expires 2027-08-19 F1 · shares: 304,608 stock options (the "Options") were granted to Mr. Kukekov on August 19, 2022 (the "Date of Grant"), pursuant to the Brain Scientific 2022 Stock Incentive Plan. The Options shall vest and become exercisable on the following schedule: (i) 61,552 Options shall vest immediately, (ii) 69,444 Options shall vest on August 30, 2022, (iii) 69,444 Options shall vest on September 30, 2022, (iv) 69,444 Options shall vest on October 30, 2022, and (v) 34,724 Options shall vest on November 15, 2022. F1 · derivative.exercise_date: 304,608 stock options (the "Options") were granted to Mr. Kukekov on August 19, 2022 (the "Date of Grant"), pursuant to the Brain Scientific 2022 Stock Incentive Plan. The Options shall vest and become exercisable on the following schedule: (i) 61,552 Options shall vest immediately, (ii) 69,444 Options shall vest on August 30, 2022, (iii) 69,444 Options shall vest on September 30, 2022, (iv) 69,444 Options shall vest on October 30, 2022, and (v) 34,724 Options shall vest on November 15, 2022. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:32 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 25,236 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-019496 · doc1.xml · derivative · entry 1 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,236 Underlying: Common Stock · 25,236 shares Expires 2031-11-04 F1 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 12,618 shares on November 4, 2021 with the remaining 12,618 shares vesting quarterly in eight nearly equal installments beginning November 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| October 01, 2021 Filed Mar 30, 2022 16:57 UTC | BRAIN SCIENTIFIC INC. BRSF · Entity 124256 | GrantOptions to Purchase Shares of Common Stock · Derivative | 2,001,873 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-22-016225 · ownership.xml · derivative · entry 1 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,873 Underlying: Common Stock · 2,001,873 shares Expires 2031-10-01 F1 · security: The stock options were issued to Mr. Kukekov pursuant to a Non-Qualified Stock Option Agreement. The stock options are fully vested and exercisable and shall expire on 10/01/2031. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 15:24 UTC | BRAIN SCIENTIFIC INC. BRSF · Entity 124256 | GrantStock Option (Right to Buy) · Derivative | 16,779 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001213900-21-004589 · ownership.xml · derivative · entry 1 Kukekov Nickolay V. · CIK 0001827573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,779 Underlying: Common Stock, par value $0.001 per share · 16,779 shares Expires 2031-01-26 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.